Hikma says it has now addressed all outstanding questions from the US Food and Drug Administration over the firm’s application for a generic version of GlaxoSmithKline’s Advair Diskus (fluticasone/salmeterol) blockbuster respiratory brand.
Having in May 2017 received an FDA complete response letter indicating that their abbreviated new drug application was not ready...




